Comparative Pharmacology
Head-to-head clinical analysis: FML S versus ISOPTO CETAPRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML S versus ISOPTO CETAPRED.
FML-S vs ISOPTO CETAPRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2 activity, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production. This results in decreased inflammation, edema, and immune cell infiltration. Sulfacetamide is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking folate synthesis and bacterial growth.
Combination of sulfonamide antibiotic (sulfacetamide) and corticosteroid (prednisolone). Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Prednisolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene production.
1-2 drops of 0.1% ophthalmic suspension into the conjunctival sac every 4 hours; may increase to every 2 hours in severe inflammation.
1-2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; in severe cases, may be administered every 1-2 hours until response then gradually taper.
None Documented
None Documented
2.8-3.5 hours; prolonged to 8-12 hours in renal impairment or in neonates
Sulfacetamide: 7-13 hours (prolonged in renal impairment); Prednisolone: 2.5-3.5 hours (independent of dose). Total duration of anti-inflammatory effect exceeds half-life due to genomic effects.
Renal (65-75% as unchanged drug and metabolites), biliary/fecal (15-25%)
Renal: sulfacetamide is excreted unchanged in urine (30-40%); prednisolone is metabolized and excreted renally (10-20%) and fecally (30-40%) as conjugates.
Category C
Category C
Ophthalmic Antibiotic/Corticosteroid Combination
Ophthalmic Antibiotic/Corticosteroid Combination